How Obstructive Sleep Apnea Treatment Is Evolving
Obstructive Sleep Apnea (OSA) is a common and serious sleep disorder characterized by repeated episodes of upper airway obstruction during sleep. Symptoms of OSA include loud snoring, excessive daytime sleepiness and observed episodes where you stop breathing during sleep. Understanding your individual risk factors is key to diagnosis and management.
OSA affects 1 in 5 adults and contributes to cardiovascular disease, metabolic dysfunction and poor quality of life. Untreated OSA is associated with serious health problems like cardiovascular disease and can reduce life expectancy. With the growth of precision medicine, digital health and behavioral interventions OSA care is moving from one size fits all to personalized approaches.
Polysomnography (PSG) is the gold standard for diagnosing OSA especially in complex or high risk cases [4] [6]. A sleep study is done in a sleep center and reviewed by a sleep specialist to ensure accurate diagnosis. As part of the assessment a healthcare provider will review your medical history and bedtime routine to evaluate risk factors and sleep patterns.
The diagnosis process involves identifying symptoms of obstructive sleep such as loud snoring, daytime sleepiness and witnessed apneas. There are different types of sleep apnea including obstructive sleep apnea and central sleep apnea. Obstructive apneas and breathing pauses are key findings during a sleep study while central sleep apnea is when the brain fails to send signals to breathing muscles resulting in central sleep disruptions. Something like this is different from other sleep-related issues such as narcolepsy and insomnia.
But recent updates support the growing role of home sleep apnea testing (HSAT), especially for patients with high pretest probability and fewer comorbidities [1] [3]. These tests get obstructive sleep apnea diagnosed. Portable devices now offer reliable data while improving access and reducing costs.
The 2015 systematic review also highlighted the emerging value of biomarkers—like IL-6 and kallikrein-1—as potential tools for assessing OSA severity [12].
Continuous Positive Airway Pressure (CPAP) is the foundation of OSA treatment especially in moderate to severe cases. Many studies have shown its effectiveness in reducing apnea events, improving sleep quality and lowering cardiovascular risk [1] [4] [5]. CPAP and other interventions keep the airway open and get sleep apnea treated.
But adherence is a major challenge. Alternatives like oral appliances, positional therapy and upper airway surgery are effective in milder cases or when CPAP is poorly tolerated [3] [6] [8]. Surgery may be necessary for patients with severe symptoms or when other therapies fail. Severe sleep apnea and severe OSA may require more aggressive or combination therapies.
Lifestyle changes like weight loss, exercise and alcohol/tobacco cessation are foundational interventions that should be part of any treatment plan [1] [3]. These lifestyle changes are key to managing mild sleep apnea and mild obstructive sleep apnea.
A comprehensive approach is often needed to get obstructive sleep apnea treated and to treat OSA.
Not all OSA cases are the same. Advances in phenotyping—the classification of patients by symptom clusters, anatomy and comorbidities—are shaping precision medicine approaches [7] [9]. This has led to new algorithms for selecting ideal therapies based on individual traits rather than a one size fits all CPAP prescription.
A 2025 phenotype-based study showed how different comorbidity profiles may predict which patients need early referral and treatment escalation [9].
The COVID-19 pandemic accelerated the adoption of telemedicine and sleep medicine was no exception. Virtual consultations, remote device monitoring and app-based interventions are being integrated into care. While current evidence is limited to consensus reports, early data suggests improved adherence and symptom tracking when digital tools are used [2].
Artificial intelligence (AI) and machine learning (ML) are being explored to streamline diagnosis, predict treatment outcomes and detect high-risk phenotypes [10]. A 2025 review noted the need for standardized datasets and validation models before widespread clinical use but the future looks promising.
Positional OSA, where apnea events occur primarily when lying on the back, has different cardiovascular outcomes and may respond to targeted interventions like positional therapy [14]. Airway obstruction in positional OSA occurs when the muscles in the back of the throat relax and the airway narrows and collapses.
Meanwhile drug-induced sleep endoscopy (DISE) in pediatric populations is gaining popularity as a tool to visualize dynamic airway collapse and guide surgical decision making [13]. Visualization during DISE often shows collapse at the level of the soft palate which guides surgical decisions.
OSA's role in metabolic disease, including type 2 diabetes, dyslipidemia, metabolic syndrome and diabetes mellitus is being uncovered [11]. Treating sleep apnea may improve insulin sensitivity and reduce systemic inflammation. Cardiovascular risks—including hypertension, arrhythmias and stroke—are significantly higher in untreated OSA patients [5] [14]. OSA is linked to high blood pressure, blood pressure fluctuations, heart failure, congestive heart failure, coronary artery disease. Repeated drops in blood oxygen levels during apnea episodes contribute to cardiovascular problems and increased risk of adverse health outcomes.
OSA management is moving beyond traditional diagnostics and CPAP therapy. Today's clinicians are using home-based testing, telehealth, AI tools and phenotype-driven care to tailor treatments and improve outcomes. While CPAP is still central, patient engagement, innovation and multidisciplinary care are shaping the future of sleep medicine.
[1] Gottlieb, D. J., & Punjabi, N. M. (2020). Diagnosis and Management of Obstructive Sleep Apnea: A Review. JAMA, 323(14), 1389–1400. https://doi.org/10.1001/jama.2020.3514
[2] Spicuzza, L., Attinà, A., Bignamini, E., Cilla, M., De Bortoli, J., Di Michele, L., Foresi, A., Malorgio, E., Marino, L., Rocca, A., Toraldo, D. M., & Sanna, A. (2025). Telemedicine in the Management of Patients with Obstructive Sleep Apnea: Evidence from the Literature and Practical Issues. A Consensus Document from the Task Force for Telemedicine in Respiratory Diseases, Part of the Italian Society of Telemedicine. Telemedicine journal and e-health : the official journal of the American Telemedicine Association, 10.1089/tmj.2024.0573. Advance online publication. https://doi.org/10.1089/tmj.2024.0573
[3] Maher, L. L. M., & Coke, L. A. (2021). Diagnosis and treatment of obstructive sleep apnea and its impact on cardiovascular disease. Journal of the American Association of Nurse Practitioners, 34(2), 389–396. https://doi.org/10.1097/JXX.0000000000000632
[4] Semelka, M., Wilson, J., & Floyd, R. (2016). Diagnosis and Treatment of Obstructive Sleep Apnea in Adults. American family physician, 94(5), 355–360. https://pubmed.ncbi.nlm.nih.gov/27583421/
[5] White D. P. (2006). Sleep apnea. Proceedings of the American Thoracic Society, 3(1), 124–128. https://doi.org/10.1513/pats.200510-116JH
[6] Hynes, D., & Mansfield, D. (2024). Diagnosis and management of obstructive sleep apnoea in adults. Australian prescriber, 47(2), 52–56. https://doi.org/10.18773/austprescr.2024.010
[7] Labarca, G., Henríquez-Beltrán, M., & Solomons, D. (2025). Precision Medicine to Guide Obstructive Sleep Apnea Treatment Beyond the Continuous Positive Airway Pressure. Seminars in respiratory and critical care medicine, 10.1055/a-2591-5502. Advance online publication. https://doi.org/10.1055/a-2591-5502
[8] Goyal, M., & Johnson, J. (2017). Obstructive Sleep Apnea Diagnosis and Management. Missouri medicine, 114(2), 120–124. https://pubmed.ncbi.nlm.nih.gov/30228558/
[9] Yeşildağ, M., & Duksal, F. (2025). Comorbidities and anthropometric parameters in obstructive sleep apnea syndrome: a phenotype-based study. Clinical and experimental hypertension (New York, N.Y. : 1993), 47(1), 2512136. https://doi.org/10.1080/10641963.2025.2512136
[10] Araujo, M. L. D., Winger, T., Ghosn, S., Saab, C., Srivastava, J., Kazaglis, L., Mathur, P., & Mehra, R. (2025). Status and opportunities of machine learning applications in obstructive sleep apnea: A narrative review. Computational and structural biotechnology journal, 28, 167–174. https://doi.org/10.1016/j.csbj.2025.04.033
[11] Light, M., McCowen, K., Malhotra, A., & Mesarwi, O. A. (2018). Sleep apnea, metabolic disease, and the cutting edge of therapy. Metabolism: clinical and experimental, 84, 94–98. https://doi.org/10.1016/j.metabol.2017.09.004
[12] De Luca Canto, G., Pachêco-Pereira, C., Aydinoz, S., Major, P. W., Flores-Mir, C., & Gozal, D. (2015). Diagnostic capability of biological markers in assessment of obstructive sleep apnea: a systematic review and meta-analysis. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 11(1), 27–36. https://doi.org/10.5664/jcsm.4358
[13] Xiao, Z., Li, X., Zhou, L., Long, X., Tian, L., & Li, W. (2025). Drug-Induced Sleep Endoscopy and Its Recent Clinical Applications in Combination with Other Procedures in Children: A Narrative Review. Nature and science of sleep, 17, 1067–1077. https://doi.org/10.2147/NSS.S498360
[14] Kang, H., Chow, C., Lobo, J., Logan, J., Bonner, H., Cho, Y., Liu, X., Mazimba, S., & Kwon, Y. (2025). Positional obstructive sleep apnea and cardiovascular outcomes. Sleep & breathing = Schlaf & Atmung, 29(3), 190. https://doi.org/10.1007/s11325-025-03342-y
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Risk of Sleep Breathing Disorder Set to Rise 45% by End of Century
Rising temperatures could increase the chances of experiencing obstructive sleep apnea (OSA) by nearly 50 percent by the end of the century, placing a greater burden on society through loss of health, wellbeing, and productivity. This is the result of a recent investigation into the effects of local temperature increases on OSA, a condition where a person's airways become blocked while sleeping for more than 10 seconds at least five times an hour throughout the night. "This study helps us to understand how environmental factors like climate might affect health by investigating whether ambient temperatures influence the severity of OSA," says sleep scientist Bastien Lechat from Flinders University in Australia, who led the study. "Overall, we were surprised by the magnitude of the association between ambient temperature and OSA severity." Many of the nearly 1 billion people globally with this sleep disorder don't even know they have it, yet it can take a serious toll on their health. Aside from affecting sleep quality, OSA alters the levels of oxygen and carbon dioxide in the blood. In the long term, this imbalance can affect insulin and glucose metabolism, mental function and mood, and can even lead to cardiovascular problems like heart failure and stroke. Previous research has also linked untreated or severe OSA with increased risk of dementia, Parkinson's disease, traffic accidents, and all-cause mortality. Lechat and his colleagues drew on data from an under-mattress sleep sensor used by 116,620 people across 29 countries between January 2020 and September 2023. The sensor detects movement and sound which can be analyzed to create estimates of sleep timing, quality, and breathing. The researchers matched this data – around 500 separate nights per person – with detailed, 24 hour temperature data for participant's nearest cities. In 2023, this coincided with the highest mean temperature recordings on record in over 2000 years, 2.07 °C above pre-industrial levels. "Higher temperatures were associated with a 45 percent increased likelihood of a sleeper experiencing OSA on a given night," Lechat says. "The increase in OSA prevalence in 2023 due to global warming was associated with a loss of approximately 800,000 healthy life years across the 29 countries studied. This number is similar to other medical conditions, such as bipolar disorder, Parkinson's disease or chronic kidney diseases." They estimate that the resulting wellbeing burden and workplace productivity loss cost economies a total of around $98 billion USD, with an estimated 105 million days of workplace productivity lost. All up, this would double the condition's estimated burden on society compared with today. "Importantly, these findings varied by region, with people in European countries seeing higher rates of OSA when temperatures rise than those in Australia and the United States, perhaps due to different rates of air conditioning usage," Lechat adds. Because the sleep sensors from which the data were collected are more readily available to people in higher socioeconomic countries and individuals, this study may actually underestimate the true health and economic cost of OSA exacerbated by climate change. These people may have access to better sleep environments and air conditioning, the researchers point out, mitigating the effect of temperature on their sleep. Modeling based on government climate change policies from 2020 suggests global warming will raise temperatures by around 2.1–3.4 °C by 2100, unless greenhouse gas emissions are further reduced. "The health and economic impact of these estimates would be consequential, and the increase in OSA prevalence due to rising temperatures in such scenario may double the overall OSA burden," the authors report. The research was published in Nature Communications. Breakthrough: FDA Approves Injection to Prevent HIV Is It Gastro or Food Poisoning? Here's A Guide to Your Upset Stomach Axolotl Discovery Brings Us Closer Than Ever to Regrowing Human Limbs
Yahoo
5 days ago
- Yahoo
Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X
Top-line results expected July 2025 as development of first-in-class OSA drug advances NEW YORK and MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ('Incannex' or the 'Company'), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, is pleased to announce that it has achieved database lock for the RePOSA Phase 2 clinical trial of IHL-42X, its lead drug candidate for obstructive sleep apnoea (OSA), on schedule as of 16 June 2025. This marks a major milestone in the development of IHL-42X, confirming the completion of clinical data collection and enabling final statistical analysis to begin. The Company is on track to deliver top-line results in July 2025, reinforcing confidence in the program's momentum and execution. Joel Latham, President and CEO of Incannex, commented, "Achieving database lock on schedule demonstrates our strong clinical capabilities and commitment to advancing a much-needed therapy for obstructive sleep apnoea. IHL-42X represents a breakthrough opportunity to address a condition affecting hundreds of millions of people globally, with no approved oral pharmacological treatment available. We are excited by what lies ahead." The RePOSA Phase 2 trial is evaluating IHL-42X in patients with moderate to severe OSA who are unable or unwilling to use continuous positive airway pressure (CPAP). The proprietary fixed-dose combination therapy is designed to reduce apnoea episodes, improve sleep quality, and offer a patient-friendly alternative to current treatment options. With over 900 million people affected by OSA worldwide and growing awareness of its impact on cardiovascular and metabolic health, IHL-42X is positioned to disrupt the treatment paradigm and deliver meaningful clinical benefit to a vastly underserved patient population. This achievement builds on positive results from earlier studies and marks the next step in the Company's strategy to commercialise IHL-42X as a first-in-class, market-leading therapeutic solution for OSA. About IHL-42XIHL-42X is designed to treat obstructive sleep apnea ('OSA') by targeting its underlying pathophysiology. An oral fixed-dose combination of dronabinol and acetazolamide, IHL-42X is currently advancing through the RePOSA Phase 2/3 clinical trial, which is expected to enroll more than 560 patients at sites worldwide. Designed to act synergistically, IHL-42X uniquely targets two physiological pathways associated with the intermittent hypoxia ('IH') and hypercapnia that characterize OSA. In a prior Australian Phase 2 clinical trial, IHL-42X was shown to reduce the Apnea-Hypopnea Index ('AHI') in all dosage strengths, with the lowest dose reducing AHI by an average of 51 percent relative to baseline. RePOSA, a global Phase 2/3 clinical trial is underway, evaluating IHL-42X in individuals with OSA who are either non-compliant, intolerant, or naïve to positive airway pressure devices, including CPAP, with the Phase 2 portion conducted in the United States. A topline readout from the U.S. Phase 2 portion is anticipated in July 2025. Unlike weight loss therapies, IHL-42X is uniquely engineered to target two key physiological pathways, intermittent hypoxia (IH) and hypercapnia, that underlie the pathology of OSA. By targeting these core mechanisms, IHL-42X offers a differentiated approach that may benefit a wider range of patients, including the 67% of individuals with OSA who are not classified as obese. OSA affects an estimated 1 billion people globally and approximately 30 million people in the United States. Despite its high prevalence OSA remains significantly underdiagnosed and undertreated. IHL-42X has the potential to address this critical gap in care and improve outcomes for millions living with this serious, chronic condition. About Incannex Healthcare is leading the way in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. The company is advancing three clinical-stage product candidates based on evidence-based innovation, and supported by streamlined operations. Incannex's lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnea. In a Phase 2 development program, IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. Approved for Phase 2 clinical development, PSX-001 is an oral synthetic psilocybin treatment for the treatment of generalized anxiety disorder. Incannex's programs target disorders that have limited, inadequate, or no approved pharmaceutical treatment options. For additional information on Incannex, please visit our website at Forward Looking StatementsThis press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: Incannex's business strategy, future operations; Incannex's judgements regarding the potential benefits from the cancellation of its Series A Warrants; Incannex's ability to execute on its objectives, prospects, or plans, evaluations and judgments regarding Incannex's research and development efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials or final results; the expected timing of enrollment for these trials and the availability of data or results of these trials, and the potential benefits, safety or of Incannex's drug candidates. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or Incannex's future performance, and they are based on management's current assumptions, expectations, and beliefs concerning future developments and their potential effect on Incannex's business; Incannex's ability to potentially benefit from its improved capital structure or to maintain or further improve its capital structure in the future. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the continued availability of financing; Incannex's ability to raise capital to fund continuing operations, to complete capital raising transactions and to maintain or potentially further improve its capital structure; the impact of any infringement actions or other litigation brought against Incannex; the success of Incannex's development efforts, including Incannex's ability to progress its drug candidates through clinical trials on the timelines expected; competition from other providers and products; that the market for its drug candidates may not grow at the rates anticipated or at all; Incannex's compliance with the various evolving and complex laws and regulations applicable to its business and its industry; and Incannex's ability to protect its proprietary technology and intellectual property; and other factors relating to Incannex's industry, its operations and results of operations. The forward-looking statements made in this press release speak only as of the date of this press release, and Incannex assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law. Incannex's reports filed with the U.S. Securities and Exchange Commission (SEC) including its annual report on Form 10-K for the fiscal year ended June 30, 2024, filed with the SEC on September 30, 2024, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, are made available on Incannex's website upon their filing with the SEC. These reports contain more information about Incannex, its business and the risks affecting its business, as well as its results of operations for the periods covered by the financial results included in this press release. For additional information on Incannex, please visit our website at Investor & Media Contacts CORE IR(212) 655-0924investors@ media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Yahoo
Peer-Reviewed Study Validates Accuracy of SANSA Home Sleep Apnea Test
ATLANTA, Ga., June 17, 2025 /PRNewswire/ -- Huxley Medical, a commercial-stage medical technology firm focused on streamlining detection of sleep and heart disorders, announced that the clinical validation study of its SANSA home sleep apnea test has been published in Frontiers in Neurology (Volume 16, 2025; doi: 10.3389/fneur.2025.1592690). The multicenter, prospective trial confirms that SANSA delivers comparable performance to in–lab polysomnography (PSG), the recognized gold standard for obstructive sleep apnea (OSA) diagnosis. The study, titled "Polysomnography validation of SANSA to detect obstructive sleep apnea," included 340 participants across seven U.S. clinical sites. SANSA's close agreement with PSG combined with its simple, single-point-of-contact, hands-free design positions it as an efficient and versatile solution to diagnose and monitor OSA. Study highlights include: Scale and diversity: Investigators highlighted the generalizability of the study results due to its large, diverse group of participants across seven academic and community sleep centers using different PSG protocols, exceeding that of most other home sleep testing study validations. Diagnostic accuracy: High apnea-hypopnea index (AHI) correlation with consensus PSG (91%), along with sensitivity of 88% and specificity of 87% for detecting moderate-to-severe OSA (AHI ≥ 15 events/hour) Total sleep time assessment: Correlation of R = 0.82 between SANSA and PSG-derived measures, with sleep epoch classification accuracy of 87% "This publication represents an important milestone in the clinical validation of SANSA," said Dr. Cathy Goldstein, MD, principal investigator on the study, professor of Neurology at the University of Michigan Sleep Disorders Center, and former chair of the American Academy of Sleep Medicine's Artificial Intelligence in Sleep Medicine Committee. "As providers seek more efficient and scalable ways to diagnose sleep apnea, these findings reinforce that SANSA can deliver reliable, high-quality data without the complexity of traditional home sleep apnea testing devices." The SANSA platform uses a wireless chest-worn patch to collect multi-parameter physiological data without the need for phone apps or technician setup. By simplifying testing, SANSA aims to expand access to timely diagnosis and treatment for millions of Americans with undiagnosed sleep apnea. The embedded reference electrocardiogram (ECG) within SANSA's suite of sensors also enables concurrent measurement of cardiac signals—opening new avenues for broader clinical applications. About Huxley MedicalHuxley Medical, Inc. is a privately held medical technology company on a mission to develop diagnostic solutions that streamline care for any patient anywhere. The company has received funding from the National Science Foundation, National Institutes of Health, Georgia Research Alliance Venture Fund, Invest Georgia, Georgia Tech Foundation Research Impact Fund, and Duke Capital Partners to translate its growing technology portfolio. To learn more, visit or email info@ Research manuscript: Media ContactBrennan TorstrickChief Scientific OfficerHuxley View original content to download multimedia: SOURCE Huxley Medical, Inc. Sign in to access your portfolio
